Roche snags rights to South Korean obesity treatment

Genentech, the Californian subsidiary of Swiss pharmaceutical giant Roche, has secured worldwide rights to develop, manufacture and market an experimental treatment for obesity from the South Korean company Hanmi Pharmaceuticals. The agreement excludes South Korea, Hanmi stated in a press release issued today. + Can Swiss pharma giant Roche reshape the obesity market? Hanmi stands to receive a total of $2.3 billion under the agreement, a figure largely contingent upon the achievement of clini...

By swissinfo.ch